Clinical research associates experience with missing patient reported outcomes data in cancer randomized controlled trials

被引:2
|
作者
Palmer, Michael J. [1 ,2 ]
Krupa, Terry [3 ]
Richardson, Harriet [1 ,2 ]
Brundage, Michael D. [1 ,2 ]
机构
[1] Queens Univ, Dept Publ Hlth Sci, Kingston, ON, Canada
[2] Queens Canc Res Inst, Canc Care & Epidemiol, Kingston, ON K7L 3N6, Canada
[3] Queens Univ, Sch Rehabil Therapy, Kingston, ON, Canada
来源
CANCER MEDICINE | 2021年 / 10卷 / 09期
关键词
data quality; patient reported outcomes; qualitative research; randomized controlled trial; STRATEGIES;
D O I
10.1002/cam4.3826
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Missing patient reported outcomes data threaten the validity of PRO-specific findings and conclusions from randomized controlled trials by introducing bias due to data missing not at random. Clinical Research Associates are a largely unexplored source for informing understanding of potential causes of missing PRO data. The purpose of this qualitative research was to describe factors that influence missing PRO data, as revealed through the lived experience of CRAs. Methods Maximum variation sampling was used to select CRAs having a range of experiences with missing PRO data from academic or nonacademic centers in different geographic locations of Canada. Semistructured interviews were audio-recorded, transcribed verbatim, and analyzed according to descriptive phenomenology. Results Eleven CRAs were interviewed. Analysis revealed several factors that influence missing PRO data that were organized within themes. PROs for routine clinical care compete with PROs for RCTs. Both the paper and electronic formats have benefits and drawbacks. Missing PRO data are influenced by characteristics of the instruments and of the patients. Assessment of PROs at progression of disease is particularly difficult. Deficiencies in center research infrastructure can contribute. CRAs develop relationships with patients that may help reduce missing PRO data. It is not always possible to provide sufficient time to complete the instrument. There is a need for field guidance and a motivation among CRAs to contribute their knowledge to address issues. Conclusion These results enhance understanding of factors influencing missing PRO data and have important implications for designing operational solutions to improve data quality on cancer RCTs.
引用
收藏
页码:3026 / 3034
页数:9
相关论文
共 50 条
  • [1] The lived experience of clinical research associates with missing patient-reported outcome data in cancer randomized clinical trials
    Palmer, Michael
    Krupa, Terry
    Richardson, Harriet
    Brundage, Michael
    QUALITY OF LIFE RESEARCH, 2020, 29 (SUPPL 1) : S155 - S156
  • [2] IMPROVING THE QUALITY OF PATIENT REPORTED OUTCOMES IN RANDOMIZED CLINICAL TRIALS BY MINIMIZING MISSING DATA
    Palmer, Michael
    Richardson, Harriet
    Brundage, Michael
    RADIOTHERAPY AND ONCOLOGY, 2020, 150 : S18 - S18
  • [3] Concordance between patient reported and clinical outcomes in randomized controlled trials (RCTs) of cancer treatment
    Efficace, Fabio
    Aaronson, Neil K.
    Sparano, Francesco
    Sprangers, Mirjam
    Fayers, Peter
    Pusic, Andrea L.
    Anota, Amelie
    Cottone, Francesco
    Rees, Jonathan
    Deliu, Nina
    Piciocchi, Alfonso
    La Sala, Edoardo
    Haas, Alissa
    Kieffer, Jacobien M.
    Wang, Wenna
    Pezold, Mike
    Fuzesi, Sarah
    Isharwal, Sumit
    Yeung, John
    Wan, Chonghua
    Blazeby, Jane
    QUALITY OF LIFE RESEARCH, 2017, 26 (01) : 103 - 104
  • [4] PATIENT-REPORTED OUTCOMES IN RANDOMIZED CLINICAL TRIALS
    Shoulson, I.
    MUSCLE & NERVE, 2014, 50 : S2 - S2
  • [5] Investigating methodology of Patient-Reported Outcomes data analysis in breast cancer randomized clinical trials
    Anota, Amelie
    Fiteni, Frederic
    Cottone, Francesco
    Pusic, Andrea L.
    Sparano, Francesco
    Fuzesi, Sarah
    Bonnetain, Franck
    Efficace, Fabio
    QUALITY OF LIFE RESEARCH, 2017, 26 (01) : 117 - 118
  • [6] Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review
    Charton E.
    Cuer B.
    Cottone F.
    Efficace F.
    Touraine C.
    Hamidou Z.
    Fiteni F.
    Bonnetain F.
    Woronoff-Lemsi M.-C.
    Bascoul-Mollevi C.
    Anota A.
    Quality of Life Research, 2020, 29 (4) : 867 - 878
  • [7] What are the appropriate methods for analyzing patient-reported outcomes in randomized trials when data are missing?
    Hamel, J. F.
    Sebille, V.
    Le Neel, T.
    Kubis, G.
    Boyer, F. C.
    Hardouin, J. B.
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2017, 26 (06) : 2897 - 2908
  • [8] OUTCOMES REPORTED IN CLINICAL TRIALS OF ROSACEA: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS
    Ibrahim, Sarah
    Kang, Bianca
    Iyengar, Sanjana
    Schlessinger, Daniel
    Maher, Ian
    Sobanko, Joseph
    Cartee, Todd
    Poon, Emily
    Alam, Murad
    LASERS IN SURGERY AND MEDICINE, 2021, 53 : S24 - S24
  • [9] OUTCOMES REPORTED IN CLINICAL TRIALS OF MELASMA: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS
    Kang, Bianca
    Ibrahim, Sarah
    Chiren, Sarah
    Schlessinger, Daniel
    Tang, Jennifer
    Poon, Emily
    Maher, Ian
    Sobanko, Joseph
    Cartee, Todd
    Alam, Murad
    LASERS IN SURGERY AND MEDICINE, 2021, 53 : S20 - S21
  • [10] Patient reported outcomes in randomized controlled cancer trials in advanced disease: a structured literature review
    Weingaertner, V.
    Dargatz, N.
    Weber, C.
    Mueller, D.
    Stock, S.
    Voltz, R.
    Gaertner, J.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (06) : 821 - 829